Abstract: Alopecia areata is believed to be an autoimmune disease resulting from a breach in the immune privilege of the hair follicles causing non scarring hair loss. Methods: our study included 40 patients from may 2019 to july 2022 diagnosed clinically, dermatoscopically and pathologically as alopecia areata Data were enrolled from department of dermatology and venereology, Al-Hussein hospital.
Age range
16 Years – 60 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Mac Donald Hull and Norris grading system
Timeframe: 4 weeks after the end of treatment
Scoring of texture of regrown hair
Timeframe: after each session and 4 weeks after the end of treatment
Scoring of pigmentation of regrown hair
Timeframe: after each session and 4 weeks after the end of treatment
Scoring for density of hair regrowth
Timeframe: after each session and 4 weeks after the end of treatment
Scoring of overall response at the end of the study
Timeframe: after each session and 4 weeks after the end of treatment
histopathological changes
Timeframe: after each session and 4 weeks after the end of treatment
trichoscopic parameters
Timeframe: after each session and 4 weeks after the end of treatment